For those of us accustomed to reading criticism of pharmaceutical companies for putting “profits before people”, the news that GlaxoSmithKline has developed a product that the company predicts will never make a profit, may surprise many.

In a move that will no doubt generate much debate among industry critics and supporters alike, GSK announced on 30 March that they have made an application to the European Medicines Agency (EMEA) for a scientific opinion on a combination vaccine called Globorix intended for use only in Africa.

Globorix is primarily a conjugate meningitis A and C vaccine, but it will protect against a host of other diseases that kill many children in Africa and elsewhere including diphtheria, tetanus, pertussis, hepatitis B and haemophilus influenza type b.

Upcoming Ethical Corporation conferences & events:
How to manage Social & Environmental Risk in the mining, oil & gas, steel and other heavy industries
London, 22-23 March 2010 The Responsible Business Summit 2010
Novotel West Hotel, London, 4th – 5th May 2010 The Inaugural Ethical Corporation Awards
Novotel West Hotel, London, Evening of 4th May 2010
The Awards will be held at the Responsible Summit -
on the evening of the first day
Please login to view whole article - or subscribe here.
For a free two week trial to Ethical Corporation online, please click here.